search
Back to results

Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

Primary Purpose

Osteoarthritis, Acetaminophen, Arthroplasty, Hip Replacement

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Intravenous acetaminophen
Oral acetaminophen
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

56 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients scheduled for elective, primary total hip replacement for osteoarthritis
  • American Society of Anesthesiologists (ASA) Physical Classification I-III
  • Weight 50 kg or greater
  • Body mass index 18-40 kg/m2

Exclusion Criteria:

  • Inability to consent to study
  • Inability to speak English
  • Pregnancy
  • Weight <50 kg
  • Revision hip replacement or emergency surgery
  • Contraindications to spinal anesthesia: coagulopathy or bleeding diathesis, local infection, allergy to local anesthetics
  • Allergies/intolerances/contraindications to any of the multimodal agents: acetaminophen, pregabalin, celecoxib, ketamine, or dexamethasone
  • Chronic pain from a separate source other than operative hip
  • Daily opioid equivalent use of 30 mg of morphine or greater at time of consent
  • History of heart failure
  • History of drug or alcohol abuse
  • Rheumatoid arthritis
  • Uncontrolled anxiety, schizophrenia or other psychiatric disorder that, in the opinion of the investigator, may interfere with the study assessments
  • Chronic malnutrition, renal or liver impairment
  • Hypersensitivity to acetaminophen or any of its excipients

Sites / Locations

  • Duke University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intravenous acetaminophen

Oral acetaminophen

Arm Description

Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.

Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.

Outcomes

Primary Outcome Measures

24 Hour Opioid Consumption
Cumulative dose of hydromorphone consumed in the first 24 hours postoperatively

Secondary Outcome Measures

Opioid Consumption (Other)
morphine equivalent units of intravenous and oral opioids
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively)
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Subject Satisfaction at 24 Hours
Overall subject satisfaction with hospital experience at the 24 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Subject Satisfaction at 48 Hours (48 Hours)
Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Straight Leg Raise
Number of participants who are able to complete the active straight leg test. The subject rests supine and is asked to lift his/her operative lower limb (with knee extended) until the ankle is 20 cm from level. If the subject can do this, the test is positive.
Heel Slide Test
Number of participants who are able to complete the heel-slide test. The subject rests supine and is asked to place the heel of his/her operative side on the contralateral knee, then slide the heel down to the ankle and back in one continuous motion. If the subject can do this, the test is positive. If the subject cannot do this in one motion, or if pain or other factors prevent the test from being performed, the test is negative.
Number of Participants Able to Complete the Supine to Sit Test
Number of participants able to go from supine to a sitting position independently.
Self-paced Walk Test
Time taken to walk down a hallway 20 m at a safe and quick pace, turn around and return to starting point.
Number of Participants With Opioid-related Adverse Events
Incidence of respiratory desaturation events, nausea, vomiting, pruritis, ileus, and constipation
Analgesic Consumption as Measured by Patient Diary
morphine equivalent units of oral opioids and other non-opioids
Worst Pain (Day 30)
Participants are asked to rate their WORST pain on POSTOPERATIVE DAY 30 on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively)
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU)
Pain scores (using NRS-11 scale) at with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours)
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours)
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours)
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Subject Satisfaction at 48 Hours
Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours)
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).

Full Information

First Posted
July 19, 2016
Last Updated
March 5, 2021
Sponsor
Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT02839876
Brief Title
Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty
Official Title
Comparison of Multimodal Analgesic Regimen With Intravenous Acetaminophen to Standard Oral Multimodal Therapy in Primary Total Hip Arthroplasty: A Randomized Controlled Double Blind Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
March 14, 2017 (Actual)
Primary Completion Date
October 2, 2018 (Actual)
Study Completion Date
October 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if intravenous acetaminophen is superior to oral acetaminophen when used as part of a multimodal pathway for primary total hip arthroplasty.
Detailed Description
This is a single center, prospective, randomized controlled study. 60 subjects will be recruited (see #6 Recruitment and Compensation below). On the day of surgery, subjects will be randomized to receive either the study intervention (intravenous acetaminophen and placebo tablets) or the control intervention (intravenous saline and active acetaminophen tablets). The Investigational Drug Service will prepare each intervention package, which will include one intravenous and one oral medication dose. Only one of these routes will be active (determined by randomization). Subjects will receive doses of both an intravenous and oral study drug every 6 hours in order to maintain blinding, and will receive a total of 4 doses of each (at 0, 6, 12 and 18 hours). The dose of acetaminophen in all cases will be 1000 mg. The volume of intravenous acetaminophen (and saline) will be 100 mL. The oral dose will consist of two (2) tablets of 500 mg each (or two matching placebo tablets). All subjects will receive a standardized anesthetic regimen for total hip arthroplasty, as follows: A) Preoperative phase Subjects will receive the following preoperative multimodal drugs: Pregabalin 75 mg PO Celecoxib 200 mg PO The interventional drugs, both IV and PO . The time that these drugs are administered will be recorded as time zero. Patients will then receive a spinal anesthetic with 12.5 mg of isobaric bupivacaine. No peripheral nerve blocks will be performed. B) Intraoperative phase All subjects will be receive propofol infusion beginning at 50 mg/kg/min and titrated to a Richmond Agitation-Sedation Scale score of -1 to -3 (drowsy to moderate sedation). Dexamethasone 10 mg IV and ketamine 0.25 mg/kg IV up to 40 mg total will be administered as part of the standard multimodal regimen. If required, subjects may receive fentanyl 25 mcg IV as needed to treat discomfort. No joint infiltration will be performed by the surgeon. C) Postoperative phase In the Post-Anesthesia Care Unit (PACU), subjects will have an intravenous patient-controlled analgesia (IVPCA) device connected and loading doses of hydromorphone administered by the PACU nurse as necessary (0.2 mg q 8 min prn). On the floor, subjects will receive: Pregabalin 75 mg PO BID until discharge Celecoxib 200 mg PO BID until discharge Dexamethasone 10 mg IV x 1 on postoperative day 1 (24 hours after the first dose) Intravenous patient-controlled analgesia (IVPCA) with hydromorphone (0.2 mg q 8 min). The remaining 3 intervention packages (IV and PO) will be administered at 6, 12 and 18 hours following the first dose. At time point 24 hours (i.e. the fifth dose of acetaminophen), all subjects will begin to receive 975 mg of oral acetaminophen, continuing every six hours until discharge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Acetaminophen, Arthroplasty, Hip Replacement

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intravenous acetaminophen
Arm Type
Experimental
Arm Description
Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
Arm Title
Oral acetaminophen
Arm Type
Active Comparator
Arm Description
Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
Intervention Type
Drug
Intervention Name(s)
Intravenous acetaminophen
Other Intervention Name(s)
Ofirmev
Intervention Description
Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
Intervention Type
Drug
Intervention Name(s)
Oral acetaminophen
Intervention Description
Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
Primary Outcome Measure Information:
Title
24 Hour Opioid Consumption
Description
Cumulative dose of hydromorphone consumed in the first 24 hours postoperatively
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Opioid Consumption (Other)
Description
morphine equivalent units of intravenous and oral opioids
Time Frame
0-48 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively)
Description
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
preoperatively
Title
Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
1 hour after arrival to PACU
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
8 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
24 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
36 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
48 hours
Title
Subject Satisfaction at 24 Hours
Description
Overall subject satisfaction with hospital experience at the 24 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Time Frame
24 hours
Title
Subject Satisfaction at 48 Hours (48 Hours)
Description
Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Time Frame
48 hours
Title
Straight Leg Raise
Description
Number of participants who are able to complete the active straight leg test. The subject rests supine and is asked to lift his/her operative lower limb (with knee extended) until the ankle is 20 cm from level. If the subject can do this, the test is positive.
Time Frame
Postoperative day 1
Title
Heel Slide Test
Description
Number of participants who are able to complete the heel-slide test. The subject rests supine and is asked to place the heel of his/her operative side on the contralateral knee, then slide the heel down to the ankle and back in one continuous motion. If the subject can do this, the test is positive. If the subject cannot do this in one motion, or if pain or other factors prevent the test from being performed, the test is negative.
Time Frame
Postoperative day 1
Title
Number of Participants Able to Complete the Supine to Sit Test
Description
Number of participants able to go from supine to a sitting position independently.
Time Frame
Postoperative day 1
Title
Self-paced Walk Test
Description
Time taken to walk down a hallway 20 m at a safe and quick pace, turn around and return to starting point.
Time Frame
Postoperative day 1
Title
Number of Participants With Opioid-related Adverse Events
Description
Incidence of respiratory desaturation events, nausea, vomiting, pruritis, ileus, and constipation
Time Frame
0-72 hours
Title
Analgesic Consumption as Measured by Patient Diary
Description
morphine equivalent units of oral opioids and other non-opioids
Time Frame
day 30
Title
Worst Pain (Day 30)
Description
Participants are asked to rate their WORST pain on POSTOPERATIVE DAY 30 on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
day 30
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively)
Description
Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
preoperatively
Title
Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU)
Description
Pain scores (using NRS-11 scale) at with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
1 hour after arrival to PACU
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours)
Description
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
8 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours)
Description
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
24 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours)
Description
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
36 hours
Title
Subject Satisfaction at 48 Hours
Description
Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied.
Time Frame
48 hours
Title
Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours)
Description
Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain).
Time Frame
48 hours
Other Pre-specified Outcome Measures:
Title
Hospital Length of Stay
Description
Time to both discharge readiness and to actual discharge
Time Frame
0-72 hours
Title
Overall Hospital Admission Costs
Description
difference in total hospital admission cost between groups
Time Frame
0-72 hours
Title
Pharmacy-related Costs
Description
difference in pharmacy-related cost between groups
Time Frame
0-72 hours
Title
Costs Related to Opioid-related Adverse Events
Description
difference in cost related to treatment of opioid-related adverse events (nausea, vomiting, pruritis, constipation, respiratory depression, dizziness) between groups
Time Frame
0-72 hours
Title
Cost Associated With Nursing Interventions and Drugs to Treat Opioid-related Adverse Events
Description
mean cost (per patient) related to nursing care of opioid-related adverse events (nausea, vomiting, pruritis, constipation, respiratory depression, dizziness) in $USD
Time Frame
0-72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
56 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients scheduled for elective, primary total hip replacement for osteoarthritis American Society of Anesthesiologists (ASA) Physical Classification I-III Weight 50 kg or greater Body mass index 18-40 kg/m2 Exclusion Criteria: Inability to consent to study Inability to speak English Pregnancy Weight <50 kg Revision hip replacement or emergency surgery Contraindications to spinal anesthesia: coagulopathy or bleeding diathesis, local infection, allergy to local anesthetics Allergies/intolerances/contraindications to any of the multimodal agents: acetaminophen, pregabalin, celecoxib, ketamine, or dexamethasone Chronic pain from a separate source other than operative hip Daily opioid equivalent use of 30 mg of morphine or greater at time of consent History of heart failure History of drug or alcohol abuse Rheumatoid arthritis Uncontrolled anxiety, schizophrenia or other psychiatric disorder that, in the opinion of the investigator, may interfere with the study assessments Chronic malnutrition, renal or liver impairment Hypersensitivity to acetaminophen or any of its excipients
Facility Information:
Facility Name
Duke University Hospital
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty

We'll reach out to this number within 24 hrs